PHARMAKON ADVISORS, LP

other names
{{ Info.Overview }}
Revenue {{ Info.Revenue | formatUSD }}
Headquarters {{ Info.Headquarters }}
cb

Adviser Profile
As of Date 04/12/2024
Adviser Type - Large advisory firm
Number of Employees 12 9.09%
of those in investment advisory functions 7 16.67%
Registration SEC, Approved, 3/30/2012
AUM* 3,128,821,083 8.07%
of that, discretionary 3,128,821,083 8.07%
Private Fund GAV* 1,818,888,411 18.78%
Avg Account Size 625,764,217 29.68%
SMA’s Yes
Private Funds 1 1
Contact Info 212 xxxxxxx
Websites

Client Types

- Pooled investment vehicles
- Other

Advisory Activities

- Portfolio management for pooled investment vehicles

Compensation Arrangments

- A percentage of assets under your management
- Performance-based fees

Recent News

Reported AUM

Discretionary
Non-discretionary
3B 2B 2B 2B 1B 827M 414M
2015 2016 2017 2018 2019 2020 2021 2022 2023

Private Funds



Employees

Private Funds Structure

Fund Type Count GAV
Fund TypePrivate Equity Fund Count1 GAV$1,818,888,411

Similar advisers

Adviser Hedge Fund Liquidity Fund Private Equity Fund Real Estate Fund Securitized Asset Fund Venture Capital Fund Other Fund Total Private Fund GAV AUM #Funds
Adviser MONOMOY CAPITAL MANAGEMENT, L.P. Hedge Fund- Liquidity Fund- Private Equity Fund1.7b Real Estate Fund- Securitized Asset Fund- Venture Capital Fund- Other Fund- Total Private Fund GAV1.7b AUM3.0b #Funds10
Adviser MSR CAPITAL PARTNERS, LLC Hedge Fund- Liquidity Fund- Private Equity Fund3.3b Real Estate Fund- Securitized Asset Fund- Venture Capital Fund- Other Fund253.6m Total Private Fund GAV3.6b AUM3.6b #Funds8
Adviser VMG PARTNERS II, LLC Hedge Fund- Liquidity Fund- Private Equity Fund3.0b Real Estate Fund- Securitized Asset Fund- Venture Capital Fund- Other Fund- Total Private Fund GAV3.0b AUM3.0b #Funds28
Adviser FIRST SENTIER INVESTORS Hedge Fund7.3b Liquidity Fund- Private Equity Fund- Real Estate Fund- Securitized Asset Fund- Venture Capital Fund- Other Fund- Total Private Fund GAV7.3b AUM3.1b #Funds1
Adviser SHORE CAPITAL PARTNERS Hedge Fund- Liquidity Fund- Private Equity Fund4.0b Real Estate Fund- Securitized Asset Fund- Venture Capital Fund- Other Fund- Total Private Fund GAV4.0b AUM4.0b #Funds25
Adviser BLUE WOLF CAPITAL PARTNERS LLC Hedge Fund- Liquidity Fund- Private Equity Fund2.8b Real Estate Fund- Securitized Asset Fund- Venture Capital Fund- Other Fund- Total Private Fund GAV2.8b AUM2.8b #Funds12
Adviser VESTAR CAPITAL PARTNERS, LLC Hedge Fund- Liquidity Fund- Private Equity Fund4.4b Real Estate Fund- Securitized Asset Fund- Venture Capital Fund- Other Fund- Total Private Fund GAV4.4b AUM3.2b #Funds34
Adviser MIDDLEGROUND CAPITAL Hedge Fund- Liquidity Fund- Private Equity Fund3.2b Real Estate Fund- Securitized Asset Fund- Venture Capital Fund- Other Fund- Total Private Fund GAV3.2b AUM3.8b #Funds21
Adviser ARGONAUT PRIVATE CAPITAL, LP Hedge Fund- Liquidity Fund- Private Equity Fund3.8b Real Estate Fund- Securitized Asset Fund- Venture Capital Fund- Other Fund- Total Private Fund GAV3.8b AUM3.5b #Funds8
Adviser COVE HILL PARTNERS, L.P. Hedge Fund- Liquidity Fund- Private Equity Fund3.1b Real Estate Fund- Securitized Asset Fund- Venture Capital Fund- Other Fund- Total Private Fund GAV3.1b AUM3.1b #Funds5

Brochure Summary

Overview

A. Pharmakon Advisors, LP (also referred to as “we”, the “Firm” and “Pharmakon”), founded in 2009, is an investment services firm specializing in investment management for private funds that are deemed to be pooled investment vehicles and their respective feeder funds (collectively the “Funds”). Pharmakon also provides certain investment advisory services to a public limited company in the UK (the “UK Trust”). Throughout this Brochure, “clients”, when used respect to the Firm, refer to the Funds and the UK Trust. The principal owners of Pharmakon are Pedro Gonzalez de Cosio and Pablo Legorreta. B. Pharmakon specializes in offering investment management services to its clients, which are comprised of the Funds and the UK Trust. In providing our advisory services to our clients, we focus on acquiring high yielding debt securities and instruments, including senior secured debt and capped return royalties with short average lives, which are securitized
or collateralized by the assets and products of life sciences companies and the royalty payments on one or more life sciences products, as applicable, which we believe will have good sales visibility during the expected life of such securities or instruments. C. Our Firm tailors our advisory services to the individual needs and specified investment mandates of our clients; however, the Firm does not tailor advisory services to the underlying individual investors in the clients. We adhere to the investment strategy set forth in our clients’ confidential private placement memoranda, investment management agreements, prospectus and other governing documents as applicable. D. We do not participate in wrap fee programs. The amount of client assets that we manage, as of December 31, 2023 is approximately $3,128,821,083, all of which are managed on a discretionary basis. We manage the Funds and the UK Trust on a discretionary basis.